ReviewClinical, cosmetic and investigational dermatology2026
The Genetics of Hidradenitis Suppurativa.
Review in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory skin disease characterized by painful nodules, abscesses, tunnels, and scarring, with substantial clinical and psychological burden. Genetic studies have revealed that HS has a complex and heterogeneous architecture, encompassing rare monogenic mutations, intermediate-frequency variants, and polygenic risk distributed across multiple loci. Familial aggregation, twin studies, and genome-wide association studies collectively demonstrate that inherited factors contribute substantially to disease susceptibility. Different genetic profiles influence disease onset, severity, and clinical phenotype. Monogenic γ-secretase mutations are associated with early-onset, severe, and extensive disease, whereas polygenic risk shapes heterogeneous presentations and may modify disease trajectory. Genetic variants implicated in HS also intersect with systemic comorbidities including inflammatory bowel disease, spondyloarthritis, coronary artery disease, and diabetes, highlighting shared pathogenic pathways. Mechanistic insights indicate that dysregulated Notch and Wnt/β-catenin signaling; keratinization and epithelial differentiation are central drivers of genotype-informed clinical trials. Despite advances, many variants remain uncharacterized, and polygenic risk scores currently have limited predictive power. Integration of genetic findings with clinical, environmental, and longitudinal phenotypic data is therefore essential to inform risk assessment, patient stratification, and early intervention. This review synthesizes current knowledge on HS genetics, emphasizing genotype-phenotype correlations, comorbidity associations, and translated opportunities, and outlines research priorities needed to advance toward precision medicine approaches for HS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.